Description:
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which the company believes is central to potentially unlocking meaningful improvements in clinical outcomes and quality of life for people with CF. Leveraging over a decade of the co-founders’ extensive research on NBD1, the company is advancing a pipeline of novel small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function.

POSITION SUMMARY:

We are seeking an accomplished and visionary Vice President of Chemistry, Manufacturing & Controls (CMC) to lead all aspects of starting material and API strategy, development, and manufacturing for our small molecule pipeline. This executive will provide technical leadership, strategic foresight, and enterprise-level thinking across the lifecycle of drug development — from candidate nomination through commercialization. The successful candidate will bring a demonstrated ability to balance technical execution with strategic thinking and operate as a player/coach. Willingness and ability to travel (both domestic and international) to manage and audit partner CDMOs is required. This role reports to the SVP, CMC.